Fabian Theis hopes the current growth in virtual-cell activity is not merely a temporary trend caused by companies adding AI to their offerings.

“And I, I hope that these are not just sort of now a kindling of, of a flame because everyone sort of adds AI to their things, but be- because pharma is really desperately, uh, needing to be cell type context specific in their screens, which at the moment they can't do yet on that scale.”